No way [Dissolution / BCS / IVIVC]

posted by Ohlbe – France, 2019-01-27 18:18 (600 d 22:01 ago) – Posting: # 19813
Views: 1,530

Dear yuvaneshwari,

» Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

» In the above scenario, can we consider for BCS based waiver approach ?

I think you have answered your own question. If solubility is the limiting factor, and your product has an improved solubility compared to the reference, how could you justify any kind of biowaiver ?

In any case: BCS-based biowaivers are only possible for class I and III products. Not the slightest chance if you're dealing with class II or IV.

Regards
Ohlbe

Complete thread:

Activity
 Admin contact
21,068 posts in 4,392 threads, 1,465 registered users;
online 16 (0 registered, 16 guests [including 6 identified bots]).
Forum time: Saturday 17:19 CEST (Europe/Vienna)

The purpose of models is not to fit the data,
but to sharpen the questions.    Samuel Karlin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5